Omeros Corporation (NASDAQ:OMER)‘s stock had its “buy” rating reaffirmed by analysts at Maxim Group in a research report issued to clients and investors on Tuesday. They currently have a $24.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $23.00. Maxim Group’s target price would indicate a potential upside of 10.50% from the company’s current price.

Several other research firms have also weighed in on OMER. Cowen and Company restated an “outperform” rating on shares of Omeros Corporation in a research note on Saturday, June 3rd. BidaskClub lowered shares of Omeros Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, June 28th. Wedbush restated an “outperform” rating and set a $47.00 price objective on shares of Omeros Corporation in a research note on Wednesday, May 10th. Cantor Fitzgerald lowered shares of Omeros Corporation from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $21.00 to $15.00 in a research note on Thursday, May 11th. Finally, WBB Securities restated a “strong-buy” rating and set a $75.00 price objective on shares of Omeros Corporation in a research note on Wednesday, June 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $32.80.

Omeros Corporation (NASDAQ:OMER) opened at 21.72 on Tuesday. Omeros Corporation has a 52-week low of $7.20 and a 52-week high of $27.09. The firm’s 50-day moving average is $21.81 and its 200 day moving average is $15.66. The firm’s market capitalization is $954.36 million.

Omeros Corporation (NASDAQ:OMER) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.02. The business had revenue of $17.15 million for the quarter, compared to the consensus estimate of $14.63 million. The company’s quarterly revenue was up 71.5% compared to the same quarter last year. During the same period last year, the firm earned ($0.32) earnings per share. Equities analysts anticipate that Omeros Corporation will post ($1.26) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/08/omeros-corporation-omer-earns-buy-rating-from-maxim-group.html.

In other Omeros Corporation news, VP Michael A. Jacobsen sold 12,000 shares of the stock in a transaction that occurred on Friday, June 16th. The shares were sold at an average price of $24.95, for a total transaction of $299,400.00. Following the transaction, the vice president now owns 19,500 shares in the company, valued at approximately $486,525. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Michael A. Jacobsen sold 24,000 shares of the stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $21.20, for a total transaction of $508,800.00. Following the transaction, the vice president now owns 2,650 shares in the company, valued at approximately $56,180. The disclosure for this sale can be found here. 13.60% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. National Asset Management Inc. acquired a new position in shares of Omeros Corporation during the first quarter worth about $158,000. Legal & General Group Plc raised its position in shares of Omeros Corporation by 7.8% in the second quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 751 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Omeros Corporation during the first quarter worth about $292,000. Highbridge Capital Management LLC acquired a new position in shares of Omeros Corporation during the first quarter worth about $330,000. Finally, American International Group Inc. raised its position in shares of Omeros Corporation by 15.2% in the first quarter. American International Group Inc. now owns 24,521 shares of the biopharmaceutical company’s stock worth $371,000 after buying an additional 3,232 shares during the last quarter. Hedge funds and other institutional investors own 45.11% of the company’s stock.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Analyst Recommendations for Omeros Corporation (NASDAQ:OMER)

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.